Wortman, B. G.
,
Creutzberg, C. L.
Putter, H.
Jürgenliemk-Schulz, I. M.
Jobsen, J. J.
Lutgens, L. C. H. W.
van der Steen-Banasik, E. M.
Mens, J. W. M.
Slot, A.
Kroese, M. C. Stenfert
van Triest, B.
Nijman, H. W.
Stelloo, E.
Bosse, T.
de Boer, S. M.
van Putten, W. L. J.
Smit, V. T. H. B. M
Nout, R. A.
Funding for this research was provided by:
KWF Kankerbestrijding (CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719, CKTO 2001–04, UL2012-5719)
Article History
Received: 12 April 2018
Revised: 26 September 2018
Accepted: 28 September 2018
First Online: 25 October 2018
<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate
: The trial protocol was approved by the Dutch Cancer Society (CKTO 2001–04) and the Ethics Committees of participating centres. Written informed consent was given by all patients.
: The PORTEC-2 study was supported by a grant from the Dutch Cancer Society (CKTO 2001–04).
: All authors consent for publication.
: The authors declare no competing interests.